Real-world India data show trastuzumab emtansine biosimilars deliver meaningful PFS and manageable safety in heavily ...
FDA approval of Filkri expands Accord’s G-CSF biosimilar portfolio, offering a short-acting option for neutropenia in cancer care.
All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
New Danish registry data confirm the safety of switching to infliximab biosimilars, showing low rates of serious adverse events in patients with inflammatory arthritis. As biosimilars continue to ...
Mayo Clinic’s Chelsee Jensen, PharmD, discusses FDA policy changes, biosimilar development hurdles, denosumab lessons, and payer access strategies. Chelsee Jensen, PharmD, BCPS, senior pharmacy ...
A new study confirms KM118, a proposed biosimilar to pertuzumab, shows pharmacokinetic similarity and safety, paving the way for affordable HER2-positive breast cancer treatments. In HER2-positive ...
The US biosimilar market evolves with 90 approvals, significant price drops, and new PBM models enhancing access to cost-effective therapies. Stakeholders across the US health care system navigated a ...
At a moment when high drug prices continue straining families and the healthcare system, the US finally has a clear opportunity to turn scientific progress into real relief for millions of patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results